• An article written by Oncoceutics highlighting the role of Dopamine Receptor D-2 (DRD2) in cancer was featured by Drug Discovery and Development, a leading life sciences industry publication. DRD2 is the binding target of Oncoceutics’ lead anti-cancer imipridone molecule ONC201.

    The article can be read here.

    DDD Magazine

Photostream